Revenue Net Income P/E P/S EBIT Dividend Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

QuiaPEG Pharmaceuticals Holding AAQS 2024

QuiaPEG Pharmaceuticals Holding AAQS

Ticker

QUIA.ST

ISIN

SE0001384850

WKN

A0X94X

Revenue Net Income P/E P/S EBIT Dividend Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

QuiaPEG Pharmaceuticals Holding has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock QuiaPEG Pharmaceuticals Holding in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

QuiaPEG Pharmaceuticals Holding Aktienanalyse

What does QuiaPEG Pharmaceuticals Holding do?

QuiaPEG Pharmaceuticals Holding AB is a Swedish company specialized in the research and development of medications for various diseases. The company was founded in Stockholm in 2009 and has since become a leading biotechnology company. QuiaPEG Pharmaceuticals aims to accelerate the discovery and development of medications to provide more effective therapies to patients worldwide. The company's business model is based on partnerships with large global pharmaceutical and biotech companies to develop and market medications. The company operates in multiple areas, including the research and development of cancer therapies, infectious diseases, autoimmune diseases, and neurodegenerative diseases. QuiaPEG Pharmaceuticals focuses on treating serious diseases that currently lack effective medications or have inadequate treatment options. The company has a pipeline of products in development, including new cancer therapies that target cancer cells without affecting healthy cells. Another product currently in development is a new medication for treating autoimmune diseases, addressing the underlying disease rather than just relieving symptoms. QuiaPEG Pharmaceuticals also specializes in developing medications for treating infectious diseases such as hepatitis B and C and HIV, serious diseases that have not yet been fully cured. The company is actively researching medications that can block the infection process or prevent virus spread in the body. Another important area of focus for the company is research on neurodegenerative diseases such as Alzheimer's and Parkinson's. QuiaPEG Pharmaceuticals is working on new compounds that can help halt disease progression and alleviate symptoms. The company has established extensive research collaborations with state-of-the-art laboratories and research centers worldwide to accelerate development and research. QuiaPEG Pharmaceuticals has an effective analysis platform for identifying potential drug candidates, significantly expediting the drug development process. In summary, QuiaPEG Pharmaceuticals Holding AB is a company focused on researching and developing medications to treat serious diseases. The company has a diverse pipeline of developments and collaborates extensively with leading research and development centers worldwide. QuiaPEG Pharmaceuticals aims to provide effective therapies to patients and make a significant contribution to the field of biotechnology. QuiaPEG Pharmaceuticals Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Frequently Asked Questions about QuiaPEG Pharmaceuticals Holding stock

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von QuiaPEG Pharmaceuticals Holding

Our stock analysis for QuiaPEG Pharmaceuticals Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of QuiaPEG Pharmaceuticals Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.